Product Launch Announcement: Dasib 50 (Dasatinib 50mg) Tablet
We are proud to introduce Dasib 50 is an oral targeted anti-cancer therapy containing Dasatinib 50mg, developed for the treatment of specific hematological malignancies. As a potent tyrosine kinase inhibitor, Dasib 50 offers effective disease control in patients with chronic myeloid leukemia and related conditions, supporting improved clinical outcomes through precision targeting.
🔍 Product Overview
Generic Name: Dasatinib
Strength: 50mg
Formulation: Tablet
Primary Indications:
Dasib 50 (Dasatinib 50) Tablet is indicated for the treatment of:
- Chronic myeloid leukemia (CML) in chronic, accelerated, or blast phase
- Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
- Patients resistant or intolerant to prior therapy
Mechanism of Action:
Dasatinib inhibits multiple tyrosine kinases, including BCR-ABL and SRC family kinases. By blocking these signaling pathways, it suppresses malignant cell proliferation and induces apoptosis in cancer cells.
💡 Key Benefits
- Potent inhibition of BCR-ABL kinase
- Effective in imatinib-resistant cases
- Rapid and durable therapeutic response
- Oral administration for patient convenience
- Suitable for long-term disease management under supervision
🎯 Target Audience
- Hematologists and oncologists
- Cancer treatment centers and hospitals
- Specialty and institutional pharmacies
- Oncology care providers
🏥 Commitment to Clinical Excellence
Dasib 50 is manufactured under strict Good Manufacturing Practices (GMP) and quality control systems. Every tablet meets rigorous standards of safety, efficacy, and consistency to support reliable leukemia management.
📦 Availability
Dasib 50 (Dasatinib 50 mg) Tablets are available through authorized distributors and healthcare supply channels. For supply inquiries, bulk orders, or regulatory documentation, please contact our sales or distribution team.
Dasib 50– Targeted therapy. Trusted outcomes.
